Targets › HAMP
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Oct 2027.
Liver-produced hormone that constitutes the main circulating regulator of iron absorption and distribution across tissues. Acts by promoting endocytosis and degradation of ferroportin/SLC40A1, leading to the retention of iron in iron-exporting cells and decreased flow of iron into plasma. (UniProt, P81172)
Open in Phaseline: the race on HAMP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Takeda | Rusfertide Hepcidin mimetic | HAMP | Phase 2 | Polycythemia Vera | Oct 2027 |
Polycythemia Vera (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.